[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Mr. Henry  Wheeler M.Sc.", "age": 40, "title": "Vice President of Investor Relations & Communication", "yearBorn": 1984, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Odile  Belzunce", "age": 44, "title": "Vice President of Compliance & Operations", "yearBorn": 1980, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Claire de Saint Blanquat", "age": 51, "title": "VP of Legal & Corporate Affairs and Secretary of the Supervisory Board", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Odile  Laurent M.B.A., Ph.D.", "age": 62, "title": "Vice President of Human Resources & Social Relations", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nicola  Beltraminelli Ph.D.", "age": 54, "title": "VP & Chief Development Officer", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.24, "open": 2.3, "dayLow": 2.23, "dayHigh": 2.3, "regularMarketPreviousClose": 2.24, "regularMarketOpen": 2.3, "regularMarketDayLow": 2.23, "regularMarketDayHigh": 2.3, "payoutRatio": 0.0, "beta": 0.947, "forwardPE": 5.0222225, "volume": 6998, "regularMarketVolume": 6998, "averageVolume": 229488, "averageVolume10days": 25360, "averageDailyVolume10Day": 25360, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 208275264, "fiftyTwoWeekLow": 1.29, "fiftyTwoWeekHigh": 3.511, "priceToSalesTrailing12Months": 10.351139, "fiftyDayAverage": 2.01008, "twoHundredDayAverage": 2.001025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 133808488, "profitMargins": -2.45868, "floatShares": 25273597, "sharesOutstanding": 92157200, "sharesShort": 386047, "sharesShortPriorMonth": 417095, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0046, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.00202, "shortRatio": 14.78, "shortPercentOfFloat": 0.007900001, "impliedSharesOutstanding": 84393504, "bookValue": 0.109, "priceToBook": 20.733946, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -49471000, "trailingEps": -0.69, "forwardEps": 0.45, "enterpriseToRevenue": 6.65, "enterpriseToEbitda": -2.699, "52WeekChange": -0.0923695, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 2.26, "targetHighPrice": 10.98, "targetLowPrice": 2.53, "targetMeanPrice": 7.83667, "targetMedianPrice": 10.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 80770000, "totalCashPerShare": 0.994, "ebitda": -49581000, "totalDebt": 30995000, "quickRatio": 2.6, "currentRatio": 2.6, "totalRevenue": 20121000, "debtToEquity": 350.86, "revenuePerShare": 0.248, "returnOnAssets": -0.21835, "returnOnEquity": -1.62908, "grossProfits": -31859000, "freeCashflow": 16109250, "operatingCashflow": -6896000, "revenueGrowth": -0.637, "grossMargins": -1.5833701, "ebitdaMargins": -2.46414, "operatingMargins": -3.24871, "financialCurrency": "EUR", "symbol": "IPHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "regularMarketTime": 1746216000, "exchange": "NMS", "messageBoardId": "finmb_426137", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.89285624, "regularMarketPrice": 2.26, "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1571319000000, "regularMarketChange": 0.01999998, "regularMarketDayRange": "2.23 - 2.3", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 229488, "fiftyTwoWeekLowChange": 0.97, "fiftyTwoWeekLowChangePercent": 0.75193805, "fiftyTwoWeekRange": "1.29 - 3.511", "fiftyTwoWeekHighChange": -1.2509999, "fiftyTwoWeekHighChangePercent": -0.35630873, "fiftyTwoWeekChangePercent": -9.23695, "earningsTimestamp": 1743055200, "earningsTimestampStart": 1743055200, "earningsTimestampEnd": 1743055200, "earningsCallTimestampStart": 1743080400, "earningsCallTimestampEnd": 1743080400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.69, "epsForward": 0.45, "fiftyDayAverageChange": 0.24991989, "fiftyDayAverageChangePercent": 0.1243333, "twoHundredDayAverageChange": 0.25897503, "twoHundredDayAverageChangePercent": 0.12942119, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "displayName": "Innate Pharma", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]